STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
Andrew Joseph·
·1 min read
·
0 reactions
·
0 comments
·
8 views
GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.
Original article
STAT · Andrew Joseph
Anonymous · no account needed
Discussion
0 commentsMore from STAT
STAT+: Novo underwhelmed by drug it once fought Pfizer for
STAT·14
STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more
STAT·11
Opinion: How the Amish think about vaccines, health care costs, and much more
STAT·17
Opinion: I led the U.S. CDC response to the 2014 Ebola epidemic. The new outbreak needs massive, immediate, meticulous action
STAT·17
STAT+: Newer GLP-1s, pushback on research cuts, and a protest
STAT·20
STAT+: Up and down the ladder: The latest comings and goings
STAT·16